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Abstract 
Stenotrophomonas maltophilia is an important nosocomial organism increasingly reported with multiple-
resistance to important antimicrobial drugs. We report an isolation case of clinical Stenotrophomonas 
maltophilia from Libyan hospitals. Antibiotic susceptibility testing using automated system showed the multi-
resistant typical phenotype of Stenotrophomonas maltophilia against β-lactams drugs and sensitivity for 
trimethoprim-sulfamethoxazole (MICs>2/38μg/ml). Laboratories must understand the importance of accurate 
identification and recommendations for nosocomial infection which can be treated successfully with the 
appropriate antibiotic drugs.  
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Case history 
Stenotrophomonas maltophilia is an important nosocomial pathogen, responsible for hospital acquired infections 
and highly resistant to multiple-antibiotic drugs (1-3). Here we report the first isolation case of Stenotrophomonas 
maltophilia from local hospital in Tripoli, Libya. 
 
The case: In April 2011 a 24 year-old male suffered from post-operation wound infection in the left foot, has 
presented at a local specialized hospital, Tripoli. Three consecutive daily sampling (each consist of 2 samples) 
were sent to the laboratory and each tested accordingly by both BDXpert system (PhoenixTM System) and 
bacteriologically by culture on MacConkey, blood agar for further examination by gram stain and biochemical API 
system. 
 
The BDXpert system consistently revealed that Stenotrophomonas maltophilia was the causative agent 
(confident value 99%). Also laboratory examination on grown colonies showed gram-negative bacilli, positive 
catalase reaction and non-lactose fermenting characteristic on MacConkey agar. Antibiotic susceptibility testing 
by BDXpert system indicate resistances to ß-lactam antibiotics but susceptibility to trimethoprim-
sulfamethoxazole (MICs>2/38μg/ml)..Therapy was altered therafter to trimethoprim-sulfamethoxazole (TMP-
SMX) and ciprofloxacin (IV). 
 
Stenotrophomonas maltophilia is an emerging opportunistic pathogen that shows variable resistances to many 
classes of antibiotic drugs (3, 4). Nosocomial infections and complications due to S. maltophilia is not 
common in Libya however S. maltophilia is increasingly recognised as an important nosocomial pathogen, 
responsible for high morbidity and mortality in hospitalized patients (5, 6). Stenotrophomonas maltophilia 
encodes intrinsic and acquired resistances to many important antibiotics including broad-spectrum β-lactams 
drugs (7) and delaying antibiotic therapy is a major risk factor for mortality (8). Therefore it is important to 
accurately and quickly identify S. maltophilia.  
 
The mechanism and genetic basis of antibiotic resistance has been discussed however standardized antibiotic 
susceptibility and sensitivity for Stenotrophomonas maltophilia still undefined (4). Many antibiotic drugs are 
recommended for treatment and many studies recommended the use of trimethoprim-sulfamethoxazole as the 
drug of choice mostly combined with different drugs (4). S. maltophilia which is resistant to TMP – SXT has also 
been reported (6).  
 
Antimicrobial resistant bacteria are an increasing emerging problem (9). Such organisms [e.g. MRSA] are of 
concern as they increase mortality rates and longer hospitalisation. Stenotrophomonas maltophilia is closely 
related to other nosocomial organisms (i.e. pseudomonas) and the possibility of misidentification of such 
organisms in Libya has been previously reported (10). Strategies to compact and prevent nosocomial infections 
are urgently recommended which involve the appropriate use of antibiotic drugs and the application of strict 
management and infection control system in hospitals. Moreover laboratories play an important role in controlling 
nosocomial infections and guiding therapy.  
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